Voyager licenses gene therapy tools to Novartis
Bio Pharma Dive
MARCH 6, 2023
The Swiss drugmaker's decision is the latest in a string of partnership announcements for the gene therapy maker, which aims to bounce back from past research failures
Bio Pharma Dive
MARCH 6, 2023
The Swiss drugmaker's decision is the latest in a string of partnership announcements for the gene therapy maker, which aims to bounce back from past research failures
Scienmag
APRIL 28, 2021
— Licensing expert Bob Westervelt, who has worked to transfer Sandia National Laboratories technologies in the medical, solar and hydrogen production fields, received the 2021 Outstanding Technology Transfer Professional Award from the Federal Laboratory Consortium.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Phorum
SEPTEMBER 27, 2022
While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics.
Bio Pharma Dive
OCTOBER 12, 2022
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release
Pharmaceutical Technology
DECEMBER 8, 2022
The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology. Kite Pharma and Daiichi Sankyo have updated a partnership agreement signed in 2017 for the former’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel).
Bio Pharma Dive
MAY 12, 2021
The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed
Pharmaceutical Technology
JANUARY 31, 2023
Gene therapy company uniQure has entered into a global licensing agreement with Apic Bio for APB-102 to treat patients with amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1).
Pharma Phorum
JANUARY 9, 2023
Swiss biotech Stalicla has continued to diversify its pipeline from a focus on autism therapies with a deal to license Novartis’ mavoglurant, in clinical trials for cocaine use disorder (CUD) as well as neurodevelopmental disorders (NDD).
Fierce Pharma
FEBRUARY 24, 2023
Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license esagonowsky Fri, 02/24/2023 - 09:18
Pharmaceutical Technology
MARCH 21, 2023
Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics.
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology.
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US.
Pharmaceutical Technology
MARCH 23, 2023
Biohaven has purchased the exclusive global rights for oral, brain-penetrant dual Tyrosine Kinase 2 (TYK2)/Janus Kinase 1 (JAK1) inhibitor, BHV-8000 (previously TLL-041), which treats immune-mediated brain disorders , from Hangzhou Highlightll Pharmaceutical.
Pharma Phorum
JANUARY 10, 2023
Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.
Pharma Phorum
NOVEMBER 15, 2022
Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The post Lantheus on POINT in radio-oncology with $2bn licensing deal appeared first on.
Bio Pharma Dive
OCTOBER 27, 2021
The deal with the Medicines Patent Pool is meant to increase access in lower-income countries to molnupiravir, an experimental drug that could become the first oral treatment for COVID-19
Pharma Mirror
OCTOBER 1, 2022
The post Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc appeared first on Pharma Mirror Magazine.
Pharmaceutical Technology
JANUARY 23, 2023
The post Takeda signs licensing agreement with HUTCHMED for fruquintinib appeared first on Pharmaceutical Technology. Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter’s fruquintinib.
Pharma Phorum
JULY 8, 2022
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets.
Pharma Mirror
JANUARY 26, 2021
But, you are finally here about to get your nursing license in the state of Georgia. When applying for a nursing license or getting your old one renewed, you might face some trouble if the background check doesn’t show up clean.
Pharmaceutical Technology
JANUARY 6, 2023
The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology. Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform.
Pharma Phorum
NOVEMBER 15, 2022
The post Roche deepens ties with Jnana with a second licensing deal appeared first on.
Bio Pharma Dive
MAY 13, 2022
The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries
Pharmaceutical Technology
OCTOBER 4, 2022
The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.
Scienmag
JANUARY 12, 2022
Latest News Ecigarettes licensed MedicinesNicholas Hopkinson at Imperial College London welcomes the move, saying this will give doctors another means to help smokers quit. E-cigarettes are currently regulated as consumer products so cannot be promoted as smoking cessation aids, he explains. Yet a Cochrane review already supports existing e-cigarettes as a smoking cessation aid, as does recently updated guidance […].
Scienmag
FEBRUARY 24, 2022
and WINNIPEG, Manitoba — A patented Purdue University invention designed to cool sows and lower their respiration rate while farrowing has been licensed to Innovative Heating Technologies for further beta testing and commercialization. WEST LAFAYETTE, Ind.,
Scienmag
MARCH 7, 2022
announced that the Institute’s electrochemical eRapid technology has been licensed to Antisoma Therapeutics Pty. Medicine & Health Antisoma cancer Diagnostics Disease eRapid facilitate Harvard immune infectious Institutes licensed sensor technology therapeutics Wyss
BioSpace
DECEMBER 21, 2022
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets
Pharmaceutical Technology
JULY 28, 2022
The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology. Melinta Therapeutics has signed a licence agreement with Cidara Therapeutics to facilitate a strategic collaboration for marketing the latter’s rezafungin in the US.
Fierce Pharma
DECEMBER 8, 2022
TherapeuticsMD lays off entire workforce after licensing products out for $153M. zbecker. Thu, 12/08/2022 - 15:35
Outsourcing Pharma
JANUARY 12, 2023
Biogen partners with Alcyone to gain access to ThecaFlex, which is able to deliver therapies into the intrathecal space. Drug Delivery
BioPharma Reporter
DECEMBER 6, 2022
Curamys, a South Korean biotech developing cell and gene therapy using cell fusion technology to treat rare intractable diseases, has signed a strategic platform licensing agreement with US tech developer, MaxCyte.
BioSpace
AUGUST 31, 2020
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21
Scienmag
JUNE 27, 2022
announce that the Wyss Institute’s affinity-based, multiplexed, electrochemical sensing technology, eRapid, has been licensed to the startup. The license, coordinated by Harvard’s Office of Technology Development (OTD), grants StataDX exclusive worldwide access to […].
Pharma Phorum
AUGUST 18, 2021
Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. .
Outsourcing Pharma
MARCH 2, 2023
A licensing agreement has been signed that will give Spanish pharma company, Ferrer, worldwide rights to a treatment for progressive supranuclear palsy (PSP).
Fossil Remedies
OCTOBER 16, 2022
To launch the best PCD pharma franchise company, you will have to acquire the necessary licenses from authorities. The next important thing is the license. Every pharma company needs a drug license number to begin distribution, marketing, and manufacturing activities.
BioPharma Reporter
JANUARY 6, 2023
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.
Pharma Phorum
JANUARY 29, 2021
US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The post Lilly adds to pain pipeline with Asahi Kasei licensing deal appeared first on.
Pharma Phorum
NOVEMBER 23, 2021
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The post Chinese tech giant Baidu licenses mRNA algorithm to Sanofi appeared first on.
BioSpace
AUGUST 16, 2020
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program
BioSpace
NOVEMBER 23, 2021
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides
BioSpace
OCTOBER 11, 2021
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day
Let's personalize your content